畜牧兽医学报 ›› 2008, Vol. 39 ›› Issue (3): 327-332.doi:

• 预防兽医 • 上一篇    下一篇

两株表达H9亚型禽流感病毒HA基因的重组鸡痘病毒的构建及其免疫效力

刘武杰;孙蕾;陈素娟;徐忠林;刘金彪;刘秀梵   

  1. 1.扬州大学兽医学院农业部畜禽传染病学重点开放实验室,扬州 225009; 2. 中国科学院微生物研究所分子病毒中心,北京 100101
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2008-03-24 发布日期:2008-03-24

Construction and Protective Efficacies of Two Recombinant Fowlpox Viruses Expressing the HA Gene of H9 Subtype AIV

LIU Wu-jie;SUN Lei;CHEN Su-juan;XU Zhong-lin;LIU Jin-biao;LIU Xiu-fan   

  1. 1. Animal Infectious Disease Laboratory, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China;2. Center for Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
  • Received:1900-01-01 Revised:1900-01-01 Online:2008-03-24 Published:2008-03-24

摘要: 将H9亚型禽流感病毒(AIV)HA基因插入到具有新复制非必需区的通用型质粒载体pP12LS中构建转移载体pP12LSH9A,再分别转染预先感染不同毒力的2种鸡痘病毒(FPV)282E4株和LP株的鸡胚成纤维细胞,经系列蓝斑筛选纯化,获得了2种重组鸡痘病毒(rFPV),分别命名为rFPV282-12LSH9A和rFPVLP-12LSH9A。将这2株rFPV在SPF鸡和带有高水平抗H9亚型AIV母源抗体的商品鸡上分别进行免疫效力试验。结果:rFPV28212LSH9A和rFPVLP12LSH9A在SPF鸡上的排毒保护率均为100%(10/10),在商品鸡上的排毒保护率分别为88%(23/26)和92%(24/26)。结果表明获得了2株在带有抗H9亚型AIV高水平母源抗体的商品鸡上免疫效力较好的rFPV。

Abstract: The HA gene from subtype H9N2 AIV was directionally inserted into the vector pP12LS, resulting in transfer vector pP12LSH9A. Then the pP12LSH9A was used to transfect the chicken embryo fibroblast cells, which were preinfected with strain 282E4 or LP of FPV, respectively. After serial blue plaque screening, we obtained two purified rFPVs: rFPV282-12LSH9A and rFPVLP-12LSH9A. SPF and antibody positive commercial chickens were immunized with the two rFPVs to investigate their protective efficacies. Chickens immunized with homologous AIV inactivated vaccine or widetype FPV served as controls.The protective efficacies of rFPV282-12LSH9A and rFPVLP-12LSH9A in SPF chickens were both 100%,those ones in commercial chickens were 88% and 92%, respectively. The results revealed that the rFPV282-12LSH9A and rFPVLP-12LSH9A are two effective candidate vaccines against H9 subtype AIV even in the presence of maternal antibodies against H9 subtype AIV.